Announcements Trials

Browse Landscape

Phase

Phase NA 4 Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 5 Lung Neoplasms 5 Brain Neoplasms 3 Prostatic Neoplasms 2 Esophageal Neoplasms 2 Carcinoma, Renal Cell 2 Carcinoma, Non-Small-Cell Lung 2 Carcinoma, Hepatocellular 2 Thoracic Neoplasms 1 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1 Osteosarcoma 1 Neuroblastoma 1 Neoplasms by Site 1 Mesothelioma, Malignant 1 Melanoma 1 Lymphoma 1 Lung Diseases 1 Gastric Adenocarcinoma 1 Detection Rate of SLN ; Accuracy Rate of Lymph Node Metastasis 1 Breast Neoplasms 1

Interventions

pembrolizumab 92 Nivolumab 56 Ipilimumab 55 Cyclophosphamide 52 Vemurafenib 28 fludarabine 27 aldesleukin 25 Interleukin-2 25 fludarabine phosphate 21 trametinib 20 dabrafenib 17 Temozolomide 14 Biopsy 14 Cisplatin 13 spartalizumab 12 atezolizumab 12 Carboplatin 11 cobimetinib 10 Specimen Handling 10 Paclitaxel 10 Introns 10 CTLA-4 Antigen 10 poly ICLC 9 binimetinib 9 Radiotherapy 9 Radiosurgery 9 MART-1 Antigen 9 tremelimumab 8 incomplete Freund's adjuvant 8 Radiation 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Melanoma × Indocyanine Green × Clear all

NCT01295931 2015-10-07

Nuclear and Near-Infrared (NIR) Imaging in Melanoma

M.D. Anderson Cancer Center

Phase 1 Completed

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡